Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Magainin Pharmaceuticals Inc.

(MAGN)

Business: Anti-infectives

An interim analysis of a Phase II/III trial showing equivalence between topical 1 and

Read the full 206 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE